Tata Consultancy Services (TCS): The IT giant reported a 1.3% decline in quarterly profit to ₹12,224 crore, with revenue rising slightly by 0.8% to ₹64,479 crore. The company announced an interim dividend of ₹30 per share.
Titan Company: Shares surged by up to 5%, driven by increased revenue from premium jewellery and gold coin sales. The company's standalone revenue rose approximately 25% in the fourth quarter, surpassing analyst expectations.
Infosys: The IT services firm extended its strategic collaboration with financial services company AIB to enhance digital transformation efforts.
Bharti Hexacom: The company has put on hold its plans to sell its infrastructure business to Indus Towers and will undertake a fresh review in consultation with its key shareholder, Telecommunications Consultants India.
Sun Pharma: The U.S. Court of Appeals ruled in favor of the company, vacating a preliminary injunction, which could have positive implications for its operations in the U.S. market.
ICICI Bank: The private sector lender reported a 14.1% year-on-year growth in deposits, reaching ₹27.15 trillion, while gross advances grew by 5.4% to ₹26.44 trillion.
Varun Beverages: The company has been identified as a key stock to buy, with a target price suggesting a potential upside of 25%.
SRF Limited: Recommended as a stock to watch, with analysts setting a target price indicating a 22% potential increase.
Indian Hotels Company: Highlighted for its growth prospects, with a target price reflecting a 16% anticipated rise.
Amber Enterprises: Considered a stock to keep in your portfolio, with analysts forecasting a 12% potential upside.
Investors should consider these developments and conduct thorough research or consult with financial advisors before making investment decisions, as market conditions can change rapidly.
Source: Taken from multiple websites
Disclaimer
The information provided in this media release is based on current facts and circumstances as of the date of publication. It may contain forward-looking statements, including but not limited to projections, expectations, or assumptions about future events or performance. These forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from those anticipated. Hester Biosciences Ltd does not undertake any obligation to update, revise, or correct any forward-looking statements based on new information or future events. This release is intended for informational purposes only and does not constitute financial, investment, or professional advice.